90 related articles for article (PubMed ID: 38690281)
1. Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study.
Gault A; Hogarth L; Williams KC; Greystoke A; Rajan N; Speight A; Lamb CA; Bridgewood A; Brown-Schofield LJ; Rayner F; Isaacs JD; Nsengimana J; Stewart CJ; Anderson AE; Plummer R; Pratt AG
BMC Cancer; 2024 Jun; 24(1):733. PubMed ID: 38877461
[TBL] [Abstract][Full Text] [Related]
2. Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies.
Augustin RC; Cai WL; Luke JJ; Bao R
Clin Cancer Res; 2024 May; 30(9):1724-1732. PubMed ID: 38236069
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Inflammatory Bowel Disease-associated Biomarkers in Patients With Immune Checkpoint Inhibitor Enterocolitis: A Retrospective Cohort Study.
Kogan L; Townsend MJ; Raj D; Levy AN; Giobbie-Hurder A; Grover S
Inflamm Bowel Dis; 2024 Jun; 30(6):1032-1035. PubMed ID: 37421640
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.
Qin Y; Huo M; Liu X; Li SC
Front Immunol; 2024; 15():1438587. PubMed ID: 38895125
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity.
Fahey CC; Gracie TJ; Johnson DB
Expert Rev Anticancer Ther; 2023 Jul; 23(7):673-683. PubMed ID: 37194222
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.
Das S; Johnson DB
J Immunother Cancer; 2019 Nov; 7(1):306. PubMed ID: 31730012
[TBL] [Abstract][Full Text] [Related]
7. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
von Itzstein MS; Yang Y; Wang Y; Hsiehchen D; Sheffield TY; Fattah F; Popat V; Ahmed M; Homsi J; Dowell JE; Rashdan S; Lohrey J; Hammers HJ; Hughes RS; Wang T; Xie Y; Gerber DE
Front Immunol; 2024; 15():1351739. PubMed ID: 38690281
[TBL] [Abstract][Full Text] [Related]
8. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
9. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
10. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
11. Association between immune-related adverse event timing and treatment outcomes.
Hsiehchen D; Naqash AR; Espinoza M; Von Itzstein MS; Cortellini A; Ricciuti B; Owen DH; Laharwal M; Toi Y; Burke M; Xie Y; Gerber DE
Oncoimmunology; 2022; 11(1):2017162. PubMed ID: 35003896
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
13. T-cell tolerant fraction as a predictor of immune-related adverse events.
Ostmeyer J; Park JY; von Itzstein MS; Hsiehchen D; Fattah F; Gwin M; Catalan R; Khan S; Raj P; Wakeland EK; Xie Y; Gerber DE
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37580069
[TBL] [Abstract][Full Text] [Related]
14. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.
Bukhari S; Henick BS; Winchester RJ; Lerrer S; Adam K; Gartshteyn Y; Maniar R; Lin Z; Khodadadi-Jamayran A; Tsirigos A; Salvatore MM; Lagos GG; Reiner SL; Dallos MC; Mathew M; Rizvi NA; Mor A
Cell Rep Med; 2023 Jan; 4(1):100868. PubMed ID: 36513074
[TBL] [Abstract][Full Text] [Related]
15. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.
Ghosh N; Postow M; Zhu C; Jannat-Khah D; Li QZ; Vitone G; Chan KK; Bass AR
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091456
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
